Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Conditions: HER2-Negative Metastatic Breast Cancer; Recurrent Ovarian Cancer Interventions: Drug: Durvalumab; Drug: Eribulin Sponsors: Amy Tiersten; AstraZeneca; Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Ovarian Cancer | Ovaries